A once-nightly oral pill helped control obstructive sleep apnea in a large, Phase III clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse.

The study, “Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial,” is published in the American Journal of Respiratory and Critical Care Medicine.

How the new pill performed

The trial, called SynAIRgy, showed that patients who took AD109 had fewer breathing interruptions during sleep, less oxygen deprivation, and improved blood oxygen levels overall. More than 40% of patients saw their OSA disease severity category improve, and 18% achieved complete disease control.